Bardet-Biedl Syndrome

Bardet-Biedl Syndrome (BBS) is a rare genetic condition that affects many different parts of the body. It is caused by changes (mutations) in genes that are responsible for the proper function of cilia, which are tiny, hair-like structures on the surface of cells. These cilia act like antennas, helping cells communicate and function correctly. When they don't work properly, it leads to the various symptoms seen in BBS. Children with BBS are usually born with extra fingers or toes and often develop severe weight gain and obesity very early in childhood. Other common issues include learning difficulties, kidney problems, and abnormalities in the reproductive system. One of the most significant impacts of BBS is on vision. The condition causes a progressive eye disease called rod-cone dystrophy. In the early stages, usually during childhood, patients may notice it is hard to see in the dark or in low light (night blindness). Over time, they gradually lose their side (peripheral) vision, creating a "tunnel vision" effect, and eventually lose their central vision and ability to see colors. Most people with BBS become legally blind by the time they reach their twenties or thirties. While there is currently no cure for BBS, a team of healthcare specialists can help manage the symptoms and improve quality of life. This includes regular eye exams, diet and exercise plans to manage weight, educational support for learning delays, and close monitoring of kidney function. Recently, new medications have been approved to help manage the severe hunger and obesity associated with the syndrome. Families are also encouraged to seek genetic counseling to better understand the condition and connect with support groups.

Condition category: Syndromic IRD

Prevalence: 1 in 100,000 in North America (>5,000 affected in the US); 1 in 125,000 to 1 in 160,000 in Europe; higher in isolated populations: 1 in 13,500 (Kuwait Bedouin), 1 in 17,500 (Newfoundland), 1 in 3,700 (Faroe Islands)

Inheritance patterns: Autosomal Recessive

Age of onset: First decade of life

Clinical overview: Bardet-Biedl Syndrome (BBS) is a rare, genetically heterogeneous, autosomal recessive disorder classified as a multisystem non-motile ciliopathy. The condition is characterized by a highly pleiotropic clinical phenotype that affects multiple organ systems. The primary clinical features include progressive retinal cone-rod dystrophy, early-onset truncal obesity, postaxial polydactyly, cognitive impairment, hypogonadism or genitourinary malformations, and renal abnormalities. Due to the progressive nature of the symptoms, the diagnosis is often delayed until the first decade of life when visual impairments become more pronounced. The underlying pathophysiology of BBS involves the dysfunction of primary cilia, which are sensory organelles critical for various cellular signaling pathways. Mutations in at least 26 identified BBS genes disrupt the assembly or function of the BBSome, a protein complex essential for intraflagellar transport within the cilium. This ciliary dysfunction leads to the mislocalization of proteins and subsequent cellular apoptosis or dysfunction across different tissues, explaining the wide array of clinical manifestations, from photoreceptor degeneration in the retina to structural and functional anomalies in the kidneys. BBS is a significant cause of syndromic retinitis pigmentosa and syndromic obesity. The condition is associated with substantial morbidity, particularly due to visual loss, which typically progresses to legal blindness by early adulthood, and chronic kidney disease, which is a major contributor to mortality. The syndrome is cataloged under various OMIM numbers depending on the specific genetic mutation, including OMIM 209900 (BBS1), 615995 (BBS18), and others, and is recognized by Orphanet under ORPHA:110. Management requires a multidisciplinary approach focused on symptomatic treatment and monitoring of systemic complications.

Patient and family guide: Bardet-Biedl Syndrome (BBS) is a rare genetic condition that affects many different parts of the body. It is caused by changes (mutations) in genes that are responsible for the proper function of cilia, which are tiny, hair-like structures on the surface of cells. These cilia act like antennas, helping cells communicate and function correctly. When they don't work properly, it leads to the various symptoms seen in BBS. Children with BBS are usually born with extra fingers or toes and often develop severe weight gain and obesity very early in childhood. Other common issues include learning difficulties, kidney problems, and abnormalities in the reproductive system. One of the most significant impacts of BBS is on vision. The condition causes a progressive eye disease called rod-cone dystrophy. In the early stages, usually during childhood, patients may notice it is hard to see in the dark or in low light (night blindness). Over time, they gradually lose their side (peripheral) vision, creating a "tunnel vision" effect, and eventually lose their central vision and ability to see colors. Most people with BBS become legally blind by the time they reach their twenties or thirties. While there is currently no cure for BBS, a team of healthcare specialists can help manage the symptoms and improve quality of life. This includes regular eye exams, diet and exercise plans to manage weight, educational support for learning delays, and close monitoring of kidney function. Recently, new medications have been approved to help manage the severe hunger and obesity associated with the syndrome. Families are also encouraged to seek genetic counseling to better understand the condition and connect with support groups.

Symptoms and clinical features: The clinical presentation of Bardet-Biedl Syndrome (BBS) evolves significantly over time, with symptoms appearing at different stages of life. In the early stage, typically at birth or during infancy, the most prominent physical finding is postaxial polydactyly (extra digits on the hands or feet). Infants usually have a normal birth weight but often experience rapid weight gain within the first year, leading to early-onset truncal obesity. Developmental delays, including delayed motor milestones (such as sitting and walking) and speech delays, are frequently noted during the toddler years. Renal structural anomalies, such as hydronephrosis or dysplastic kidneys, may also be detected early via ultrasound. During the intermediate stage, which encompasses childhood and early adolescence, visual symptoms begin to manifest. The initial ocular symptom is typically nyctalopia (night blindness) due to rod photoreceptor degeneration. Cognitive impairments and learning disabilities become more apparent as the child enters school. The hyperphagia (insatiable appetite) associated with BBS often exacerbates obesity, making weight management extremely challenging. Additionally, minor features such as dental anomalies, poor coordination (ataxia), and behavioral issues may become noticeable. In males, hypogonadism may present as micropenis or undescended testes, while females may exhibit complex genitourinary malformations. In the advanced stage, typically late adolescence and adulthood, the rod-cone dystrophy progresses to severe peripheral vision loss and eventual loss of central vision, leading to legal blindness in the second or third decade. The metabolic consequences of chronic obesity, including type 2 diabetes mellitus, hypertension, and hyperlipidemia, frequently emerge. Chronic kidney disease (CKD) may progress silently and is a major cause of morbidity, potentially advancing to end-stage renal disease requiring dialysis or transplantation. Hypogonadism becomes fully apparent with delayed or absent puberty and infertility, though some individuals can have biological children. Other late-onset complications can include liver fibrosis and cardiovascular anomalies.

Molecular pathology: Bardet-Biedl Syndrome is classified as a non-motile ciliopathy, arising from defects in the primary cilium, a sensory organelle present on the surface of most mammalian cells. The primary cilium plays a crucial role in various signaling pathways, including Hedgehog and Wnt signaling, which are vital for cellular division, polarity, and metabolism. The proteins encoded by BBS genes are integral to the biogenesis, maintenance, and function of these cilia. Specifically, seven highly conserved BBS proteins (BBS1, BBS2, BBS4, BBS5, BBS7, BBS8, and BBS9) assemble to form a stable protein complex known as the BBSome. The BBSome functions as a coat complex that sorts membrane proteins to primary cilia and mediates intraflagellar transport (IFT), the bidirectional movement of protein cargo along the ciliary axoneme. Other BBS proteins, such as BBS6 (MKKS), BBS10, and BBS12, function as chaperonin-like proteins that are essential for the proper assembly of the BBSome. When mutations occur in these genes, the assembly or function of the BBSome is compromised, leading to defective IFT. Consequently, critical receptors and signaling molecules fail to localize correctly within the cilium or are not properly cleared from it. In the retina, photoreceptor outer segments are specialized sensory cilia. BBS mutations disrupt the transport of essential proteins, such as rhodopsin, across the connecting cilium. This leads to the ectopic accumulation of these proteins in the inner segments and cell bodies of photoreceptors, causing cellular stress, inadequate homeostasis, and ultimately, apoptotic cell death. Similar ciliary dysfunction in other tissues explains the pleiotropic manifestations of BBS, such as renal cyst formation due to defective mechanosensation in kidney tubules, and obesity resulting from impaired ciliary signaling in hypothalamic neurons that regulate appetite.

Genetics: Bardet-Biedl Syndrome is primarily an autosomal recessive disorder, though more complex oligogenic inheritance patterns, such as triallelism, have been reported in some families. The condition is highly genetically heterogeneous, with at least 26 causative genes identified to date (BBS1 through BBS22/IFT74, plus ARL6, NPHP1, CCDC28B, and others). The most commonly mutated genes are BBS1, accounting for approximately 23% of cases, followed by BBS10 (15%) and BBS2 (10%). In certain populations, specific founder mutations are prevalent, such as the M390R mutation in BBS1 among individuals of Northern European descent. The genes associated with BBS encode proteins that are essential for the structure and function of primary cilia. Seven core BBSome proteins (BBS1, BBS2, BBS4, BBS5, BBS7, BBS8/TTC8, BBS9) assemble into the BBSome complex, which functions as a coat complex mediating intraflagellar transport (IFT) and sorting membrane proteins to primary cilia. Three chaperonin-like proteins (BBS6/MKKS, BBS10, BBS12) assist in BBSome assembly. Additional BBS proteins participate in cilia-related functions: BBS3/ARL6 is a small GTPase involved in BBSome membrane recruitment, BBS11/TRIM32 is an E3 ubiquitin ligase, BBS13/MKS1 and BBS14/CEP290 are involved in transition zone formation, BBS15/WDPCP participates in planar cell polarity, BBS17/LZTFL1 regulates BBSome ciliary trafficking, and BBS19/IFT27 and BBS20/IFT172 are intraflagellar transport proteins. Mutations in these genes disrupt ciliary transport, leading to the mislocalization of ciliary proteins and subsequent cellular dysfunction. Genotype-phenotype correlations in BBS are complex and not entirely predictable, partly due to the potential influence of modifier genes and epistatic interactions. However, some general trends have been observed. Patients with mutations in the BBS1 gene tend to have a milder phenotype, often presenting with better retinal function and less severe obesity compared to those with mutations in other BBS genes. BBS10 mutations are associated with more severe retinal degeneration and earlier onset of visual loss. Complete loss-of-function variants generally lead to a more severe clinical presentation than partial loss-of-function variants. The presence of additional mutations in other ciliopathy genes can also exacerbate the phenotype.

Diagnostic evaluation: The diagnosis of Bardet-Biedl Syndrome (BBS) is primarily clinical, based on established criteria originally proposed by Beales et al. (1999) and updated by Dollfus et al. (2024). The classic diagnostic framework requires the presence of either four primary features or three primary features plus two secondary features. Primary features include rod-cone dystrophy, truncal obesity, postaxial polydactyly, cognitive impairment, hypogonadism or genitourinary anomalies, and renal abnormalities. Secondary features encompass speech and developmental delays, diabetes mellitus, orodental abnormalities, cardiovascular anomalies, brachydactyly or syndactyly, ataxia, anosmia or hyposmia, and hepatic fibrosis. The 2024 Dollfus guidelines provide updated recommendations for follow-up clinical testing and propose standards of care for diagnosed patients. Clinical workup involves comprehensive ophthalmologic evaluation, including fundoscopy, which typically reveals pigmentary degeneration with early macular atrophy and vascular attenuation. Optical Coherence Tomography (OCT) can demonstrate outer retinal disruption and subretinal deposits. Electroretinography (ERG) is crucial for early detection, typically showing a mixed rod-cone dystrophy with diminished a-waves and b-waves at both scotopic and photopic light levels, and is more likely to show significant findings after age five. Renal function must be monitored closely via ultrasound and laboratory tests due to the high risk of chronic kidney disease. Genetic testing is highly recommended to confirm the diagnosis and is successful in identifying pathogenic variants in approximately 80% of cases. Multigene panels or exome sequencing are the preferred approaches due to the genetic heterogeneity of BBS. Notably, BBS genes are now included in three widely used genetic testing panels: the Uncovering Rare Obesity panel, the Renasight kidney disease gene panel, and ciliopathies panels. This has led to increased diagnosis in adults who were previously undiagnosed or told they did not have BBS because their symptoms were not severe enough. However, interpretation of genetic results requires expertise, as variants of uncertain significance are common and can lead to both false-positive and false-negative conclusions. The differential diagnosis includes other syndromic pigmentary retinopathies and ciliopathies, such as Alström syndrome, Joubert syndrome, Leber congenital amaurosis, Senior-Løken syndrome, and McKusick-Kaufman syndrome. Alström syndrome shares features like obesity and retinal dystrophy but is distinguished by the presence of neurosensory hearing loss and the absence of polydactyly and cognitive impairment.

Differential diagnosis: Differential diagnosis of Bardet-Biedl syndrome includes: (1) Alström syndrome — cone-rod dystrophy, hearing loss, obesity, cardiomyopathy, but NO polydactyly or cognitive impairment; ALMS1 mutations. (2) McKusick-Kaufman syndrome — polydactyly, hydrometrocolpos, congenital heart disease, but no retinal dystrophy; MKKS mutations. (3) Joubert syndrome — retinal dystrophy, renal disease, but with molar tooth sign on MRI and cerebellar vermis hypoplasia. (4) Senior-Løken syndrome — retinal dystrophy with nephronophthisis but no obesity or polydactyly. (5) Prader-Willi syndrome — obesity, hypotonia, hypogonadism, but no retinal dystrophy or polydactyly. (6) Cohen syndrome — retinal dystrophy, obesity, but with characteristic facial features, neutropenia; VPS13B mutations.

Natural history: The natural history of Bardet-Biedl Syndrome is characterized by the progressive onset of multisystemic clinical features, with significant variability in severity and progression among individuals. At birth, infants typically have a normal weight, and the most common congenital anomaly is postaxial polydactyly. During the first year of life, rapid weight gain often occurs, leading to early-onset truncal obesity. Developmental delays, including delayed motor milestones and speech, also become apparent in early childhood. Visual symptoms usually manifest in the first decade of life, with nyctalopia (night blindness) often being the initial symptom of rod-cone dystrophy. This is followed by a progressive loss of peripheral vision, decreased visual acuity, and diminished color discrimination. The rate of visual decline varies, but most individuals experience significant visual field loss and become legally blind by their second or third decade of life. Renal anomalies may be present at birth or develop later, and chronic kidney disease (CKD) can progress silently. In a significant portion of patients, CKD advances to end-stage renal disease requiring dialysis or transplantation, often diagnosed before the age of five in severe cases. Prognostic factors in BBS are heavily influenced by the specific genetic mutation and the severity of renal and metabolic complications. Patients with BBS1 mutations generally experience a milder disease course, particularly regarding visual preservation, compared to those with BBS10 or other mutations. The development of comorbidities such as type 2 diabetes mellitus, hypertension, and metabolic syndrome further complicates the clinical picture and can accelerate the progression of chronic kidney disease, significantly impacting long-term morbidity and mortality.

Management and treatment research: ### Current Management and Supportive Care There is no cure for Bardet-Biedl syndrome (BBS), and no approved treatment that reverses BBS-related retinal degeneration. Care is individualized and often involves a multidisciplinary team because BBS can affect vision, appetite and weight, kidney function, hormones, development, and other body systems. - **Vision care:** Regular visits with an ophthalmologist, ideally with inherited retinal disease expertise, can monitor retinal changes and address treatable concerns such as refractive errors. Low-vision rehabilitation, assistive technology, orientation and mobility training, and school or workplace accommodations can support independence. - **Weight and metabolic health:** Hyperphagia (persistent, difficult-to-control hunger) and early-onset obesity are common. Nutrition support, physical activity adapted to vision or mobility needs, and treatment of diabetes, high blood pressure, and abnormal cholesterol are important. - **Kidney care:** Structural kidney differences and chronic kidney disease require regular monitoring, often with a nephrologist. Care may include blood-pressure management and, when needed, dialysis or kidney transplantation. - **Endocrine, reproductive, and developmental care:** Diabetes, thyroid disease, hypogonadism, sleep concerns, learning differences, and developmental needs are treated using standard approaches. Surgery may be considered for polydactyly (extra fingers or toes) or significant genitourinary differences. ### Approved Therapy for BBS-Related Obesity **Setmelanotide (Imcivree)** is approved for chronic weight management in people with obesity due to BBS. It is a melanocortin-4 receptor (MC4R) agonist, meaning it activates a brain signaling pathway involved in hunger and energy balance. In BBS, this treatment can reduce hyperphagia and support weight loss for some people when used alongside a reduced-calorie nutrition plan and increased physical activity. The pivotal BBS study was **NCT03746522**. Treatment should be monitored by clinicians experienced in BBS and obesity care, including assessment of treatment response, side effects, mental health, and other health conditions. Setmelanotide does not treat retinal degeneration or restore vision. ### Investigational Retinal Gene Therapies These treatments aim to deliver a working copy of a BBS gene to retinal cells. They remain experimental and are not approved for BBS-related vision loss. - **BBS1: AXV-101 (Axovia Therapeutics).** AXV-101 uses an adeno-associated virus type 9 (AAV9) vector to deliver a functional **BBS1** gene to retinal cells through subretinal injection. A first-in-human, dose-escalation study for BBS1-related retinal degeneration is recruiting: **NCT07269665**. - **BBS10: AAV8-BBS10 (MeiraGTx / Eli Lilly / University of Iowa).** This approach uses an AAV8 vector carrying a human **BBS10** gene, delivered by subretinal injection to target photoreceptor degeneration associated with BBS10 variants. It is in a first-in-human program under the UK Medicines and Healthcare products Regulatory Agency (MHRA) Specials pathway. This route for access to an unlicensed medicine is not the same as a conventional registered clinical trial. - **BBS7: Subretinal gene therapy (OHSU).** A BBS7-targeted subretinal gene therapy has shown benefit in a naturally occurring rhesus macaque model of BBS7 disease. It remains preclinical, meaning it has not yet entered human studies. ### Clinical Trial and Registry Participation Clinical trials may provide access to investigational treatments, but eligibility, travel requirements, procedures, and potential risks vary. The recruiting AXV-101 gene-therapy study is **NCT07269665**. People with BBS may also be able to participate in studies that improve understanding of the condition and support future research. Examples include the BBS clinical registry (**NCT02329210**), the Inherited Retinal Degenerative Disease Registry (**NCT02435940**), and a recruiting real-world study of MC4R agonist therapy in BBS and severe genetic obesity (**NCT07674290**).

Outlook: The prognosis for individuals with Bardet-Biedl Syndrome (BBS) is highly variable and depends largely on the severity of organ involvement, particularly the kidneys and the eyes. Visual prognosis is generally poor; most patients experience progressive rod-cone dystrophy that leads to significant visual field loss and legal blindness by their second or third decade of life. This progressive vision loss profoundly impacts the patient's independence, education, and quality of life, necessitating early intervention with low-vision aids and specialized educational support. Systemic prognosis is heavily influenced by the presence and progression of chronic kidney disease (CKD), which is a leading cause of morbidity and mortality in BBS. Early detection and management of renal anomalies are critical. Additionally, the management of early-onset obesity and its associated metabolic complications, such as type 2 diabetes and hypertension, plays a significant role in long-term outcomes. While cognitive impairments and developmental delays can affect daily functioning, supportive therapies can improve adaptive skills. With proactive, multidisciplinary medical care to manage these systemic complications, many individuals with BBS can lead fulfilling lives despite the challenges posed by the syndrome.

Epidemiology: Bardet-Biedl Syndrome is a rare genetic disorder with a prevalence that varies significantly by geographic region and ethnicity. In North America, the prevalence is estimated at approximately 1 in 100,000 individuals (affecting more than 5,000 people in the United States). In Europe, estimates range from 1 in 125,000 to 1 in 160,000 newborns. However, the condition is notably more common in certain isolated or consanguineous populations. The prevalence is approximately 1 in 13,500 in some Bedouin communities in Kuwait, 1 in 17,500 to 1 in 18,000 in Newfoundland, Canada, and as high as 1 in 3,700 in the Faroe Islands. There are no reported sex differences in the prevalence or phenotype of BBS, affecting males and females equally. The higher incidence in specific populations is largely attributed to founder effects and higher rates of consanguinity, which increase the likelihood of inheriting two copies of the recessive pathogenic alleles responsible for the syndrome. BBS is increasingly being diagnosed in adults who were previously undiagnosed or misdiagnosed, as BBS genes are now included in common genetic testing panels such as the Uncovering Rare Obesity panel, the Renasight kidney disease gene panel, and ciliopathies panels. This expanded testing is identifying many adults whose symptoms were not severe enough for clinical diagnosis alone.

Selected references: 1. Forsyth R, Gunay-Aygun M. Bardet-Biedl Syndrome Overview. GeneReviews® [Internet]. 2003 Jul 14 [updated 2023]. PMID: 20301537 2. Forsythe E, Beales PL. Bardet-Biedl syndrome. European Journal of Human Genetics, 2013;21(1):8-13. PMID: 22713813 3. Forsythe E, Kenny J, Bacchelli C, Beales PL. Managing Bardet-Biedl Syndrome-Now and in the Future. Frontiers in Pediatrics, 2018;6:23. PMID: 29492394 4. Dollfus H, et al. Bardet-Biedl syndrome improved diagnosis criteria and management. European Journal of Human Genetics, 2024. PMID: 39085465 5. Melluso A, Secondulfo F, Capolongo G, Capasso G, Zacchia M. Bardet-Biedl Syndrome: Current Perspectives and Clinical Outlook. Therapeutics and Clinical Risk Management, 2023;19:115-132. PMID: 36741589 6. Grudzinska Pechhacker MK, et al. Comparative Natural History of Visual Function From Patients With Biallelic Variants in BBS1 and BBS10. Investigative Ophthalmology & Visual Science, 2021;62(15):26. PMID: 34940798 7. Priya S, Nampoothiri S, Sen P, Sripriya S. Bardet-Biedl syndrome: Genetics, molecular pathophysiology, and disease management. Indian Journal of Ophthalmology, 2016;64(9):620-627. PMID: 27853007 8. Argente J, et al. Setmelanotide in Bardet-Biedl Syndrome: A 52-Week Comparison with External Natural History Cohort. Obesity, 2026. PMC: 12933228 9. Tomlinson JW, et al. Should GLP-1 receptor agonist therapy be used to treat obesity in Bardet-Biedl syndrome? Journal of Clinical Investigation, 2025. PMC: 12165807 10. Dauleh H, et al. Efficacy of Semaglutide in Pediatric Patients With Bardet-Biedl Syndrome. JCEM Case Reports, 2025;3(12):luaf266. 11. Haqq AM, et al. Impact of Setmelanotide on Metabolic Syndrome Risk in Bardet-Biedl Syndrome. Journal of Clinical Endocrinology & Metabolism, 2025;110(10):e3271. 12. Hsu Y, et al. Subretinal gene therapy delays vision loss in a Bardet-Biedl Syndrome type 7 (BBS7) nonhuman primate model. Science Translational Medicine, 2023. PMC: 9841241 13. Peterson SM, et al. Bardet-Biedl Syndrome in Rhesus Macaques: A Nonhuman Primate Model of Retinal Degeneration. Experimental Eye Research, 2019. PMC: 7064310 14. Beales PL, et al. New criteria for improved diagnosis of Bardet-Biedl syndrome: results of a population survey. Journal of Medical Genetics, 1999;36(6):437-446. PMID: 10874630